期刊文献+

枸橼酸钠抗凝在危重患者连续性血液净化治疗中的应用 被引量:5

Application of anticoagulation with sodium citrate in continuous blood purification for critically ill patients
在线阅读 下载PDF
导出
摘要 目的评估枸橼酸钠抗凝在危重患者连续性血液净化治疗中的安全性和有效性。方法61例危重患者随机分为局部枸橼酸钠抗凝组(RCA组)38例和肝素组(对照组)23例,均行连续性血液净化治疗。监测活化凝血时间(ACT)、iCa、血Na+、尿素氮、肌酐等,观察体外循环凝血情况。结果RCA组滤后ACT值均较滤前显著延长(P〈0.05)。对照组治疗后ACT值较RCA组显著延长(P〈0.05)。RCT组滤器凝血分级、静脉壶凝血分级明显优于对照组俨〈0,05)。RCA组治疗前后pH、血Na+及血HCO3-未发现显著性变化(P〉0.05)。两组治疗后Cr、BUN均较治疗前显著降低(P〈0.05)。RCA组尿氮较对照组下降明显。结论局部枸橼酸钠在危重患者连续性血液净化时抗凝效果确切,并发症少,值得推广使用。 Objective To assess the safety and efficacy of anticoagulation with sodium citrate in continuous blood purification for critically ill patients. Methods 61 patients were randomly divided into sodium citrate group (n=38) and heparin group (control group, n = 23). Both groups received continuous blood purification. Activated clotting time (ACT) and levels of Ca, Na+, urea nitrogen, and creatinine were determined; coagulation in extracorporeal circulation was observed. Results ACT was markedly prolonged after hemofihion in RCA group as compared with the baseline (P〈0.05). ACT was significantly longer in the control group than in RCA group after treatment (P〈0.05). The filter clotting grading and the clotting grading of venous pot were significantly better in RCT group than in the control group (P〈0.05). pH, Na+ and HCO3-1 had no significance in RCA group before and after treatment (P〉0.05). Cr, BUN were significantly lower after treatment (P〈0.05). BUN was significantly decreased. Conclusions Topical sodium citrate anticoagulation for patients undergoing continuous blood purification is efficacious and has fewer complications. It is worth popularizing.
机构地区 台山市人民医院
出处 《国际医药卫生导报》 2013年第9期1319-1321,共3页 International Medicine and Health Guidance News
关键词 枸橼酸钠 血液净化 抗凝 Sodium citrate Blood purification Anticoagulant therapy
  • 相关文献

参考文献7

二级参考文献92

共引文献60

同被引文献39

  • 1王海涛,毛永辉,李胜利,吴华.枸橼酸-葡萄糖抗凝溶液在高危出血患者连续性血液净化中的应用[J].中华肾脏病杂志,2006,22(3):166-169. 被引量:11
  • 2戎殳,叶朝阳,孙丽君,陈静,张斌,梅长林.46.7%枸橼酸钠溶液在血液透析患者长期留置导管封管的应用[J].中华肾脏病杂志,2007,23(2):110-112. 被引量:29
  • 3To|wani A. Continuous renal-replacement therapy for acute kidney injury[J].N Eng[ J Meal,2012,367(26) :2505-2514.
  • 4Tolwani A, Wille KM. Advances in continuous renal replacement therapy., citrate antlcoagulation update[J3.Blood Purif,2012,34(2) :88-93.
  • 5Lanckohr C, Hahnenkamp K, Boschin M. Continuous renal replacement therapy with regional citrate anticoagulation., do we really know the details? [J]. Curt Opin Anaesthesiol, 2013,26(4) :428-437.
  • 6Oudemans-van Straaten HM,Kellum JA,Bel|omo R.Clinical review: antieoagulation {or continuous renal replacement therapy-hepar[n or citrate? []J. Crlt Care, 2011, 15 (1): 202-210.
  • 7Wu MY, Hsu YH, Bai CH, et al. Regional citrate versus heparin antieoagulation for continuous renal replacement therapy:a meta-analysis of randomized controlled trials~J3. Am J Kidney Dis,2012,59(6) :810-818.
  • 8J adad AR, Moore RA, Carroll D, et al.Assessing the quality of reports of randomized clinical trials: Is blinding necessary? [J-1.Control Clin Trials,1996,17(1) :1-12.
  • 9Liberati A, Altman DG~ Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and recta-analyses of studies that evaluate health care interventions: explanation and elaboration[J].J Clin Epidemiol,2009,62(10):el-34.
  • 10Moher D,Cook DJ,Eastwood S,et al.Improving the quality of reports of recta-analyses of randomized controlled trials: the QUOROM statement[J].Br J Surg, 2000,74 (2) : 107- 118.

引证文献5

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部